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Abstract
Background: Excessive proliferation of vascular smooth muscle cells and leukocytes within the
artery wall is a major event in the development of atherosclerosis. The growth suppressor p27kip1
associates with several cyclin-dependent kinase/cyclin complexes, thereby abrogating their capacity
to induce progression through the cell cycle. Recent studies have implicated p27kip1 in the control
of neointimal hyperplasia. For instance, p27kip1 ablation in apolipoprotein-E-null mice enhanced
arterial cell proliferation and accelerated atherogenesis induced by dietary cholesterol. Therefore,
p27kip1 is a candidate gene to modify the risk of developing atherosclerosis and associated ischaemic
events (i.e., myocardial infarction and stroke).
Results: In this study we found three common single-nucleotide polymorphisms in the human
p27kip1 gene (+326T>G [V109G], -79C>T, and -838C>A). The frequency of -838A carriers was
significantly increased in myocardial infarction patients compared to healthy controls (odds ratio
[OR] = 1.73, 95% confidence interval [95%CI] = 1.12–2.70). In addition, luciferase reporter
constructs driven by the human p27kip1 gene promoter containing A at position -838 had decreased
basal transcriptional activity when transiently transfected in Jurkat cells, compared with constructs
bearing C in -838 (P = 0.04).
Conclusions: These data suggest that -838A is associated with reduced p27kip1 promoter activity
and increased risk of myocardial infarction.
Background
The proliferation of leukocytes and vascular smooth mus-
cle cells (VSMCs) within the artery wall is a hallmark of
the atherosclerotic process [1]. The exposure of coronary
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arteries to chemical and mechanical injury triggers an
inflammatory response characterized by excessive arterial
cell proliferation. Progression through the cell cycle
depends on the sequential activation of several cyclin-
dependent kinases (CDKs). Activation of CDKs requires
their interaction with regulatory subunits named cyclins.
In resting cells, cyclin–CDK complexes are inhibited by
the reversible association with CDK inhibitory proteins
(CKIs) of the Cip/Kip family (p21cip1, p27kip1, and
p57kip2) and Ink4 family (p16Ink4a, p15Ink4b, p18Ink4c,
p19Ink4d) [2].
In recent years, accumulating evidence has implicated
p27kip1 as an important endogenous regulator of leuko-
cyte and VSMC proliferation in various pathophysiologi-
cal situations [3-7]. Remarkably, p27kip1 expression and
proliferation of VSMCs and leukocytes are inversely corre-
lated in human atheroma, and a significantly lower level
of p27kip1 expression has been reported in primary athero-
sclerotic and restenotic tissue versus nondiseased arterial
tissue [8-10]. We have previously shown that fat-fed mice
deficient in both apolipoprotein E (apoE) and p27kip1 dis-
play increased arterial cell proliferation and accelerated
atherogenesis compared to apoE-null mice with an intact
p27kip1 gene [11]. We also found that reconstitution of
sublethally irradiated apoE-null mice with p27kip1-defi-
cient bone marrow was sufficient to enhance arterial mac-
rophage proliferation and atherosclerosis induced by fat
feeding [12]. In view of these findings, the present study
was designed to assess whether p27kip1 is a candidate gene
to modify the risk of developing atherosclerosis and con-
secutive myocardial infarction (MI) in humans.
Results
Identification of p27kip1 polymorphisms and genotyping of 
MI patients and controls
The complete coding sequence as well as 1500 base pairs
of the promoter region of the human p27kip1 gene were
analysed through single-strand conformation analysis
(SSCA) in 50 MI patients and 50 controls. As shown in
Fig. 1, we identified different electrophoretic patterns in
p27kip1 DNA fragments obtained with primers P3-F+P3-
R3, P1-F+P1-R, and E1-F+E1-R (Table 1). After direct
sequencing, we identified three single-nucleotide poly-
morphisms (SNPs) within the human p27kip1  gene:
+326T>G (V109G), -79C>T, and -838C>A (nucleotide
positions numbered relative to the start of transcription
according to Genbank accession number AB003688).
+326T>G (V109G) and -79C>T have been previously
described (rs2066827 and rs34330, respectively), and -
838C>A is a novel polymorphism. +326T>G (V109G) is a
missense polymorphism in exon 1 which has been previ-
ously analysed in the context of susceptibility to several
types of cancer [13-15]. This polymorphism lies within
the domain of p27kip that is required for interaction with
p38jab1, a protein–protein association that promotes
p27kip1 proteolysis [16]. The -79C>T is a polymorphism
within a U-rich element in the 5' untranslated sequence of
p27kip1 which is necessary for the translation of the p27kip1
mRNA [17].
To genotype these polymorphisms in MI patients and
controls, we developed a protocol based on endonuclease
digestion of DNA fragments obtained by amplification
with the primers shown in Table 2. Table 3 summarizes
the genotype and allele frequencies for the three polymor-
phisms in 180 MI patients and 250 controls. The frequen-
cies for the -79C>T and +326T>G (V109G)
polymorphisms did not differ between the two groups.
For the -838C>A polymorphism, the A allele was signifi-
cantly more frequent in cases compared to control sub-
jects (P = 0.002; OR = 1.53; 95%CI = 1.15–2.03). Carriers
of the A allele (AA+AC genotypes) would have an almost
twofold risk of suffering an episode of MI compared to
controls (P = 0.009; OR = 1.73; 95%CI = 1.12–2.70).
Functional effect of the -838C>A polymorphism in the 
promoter region of the human p27kip1 gene
Having demonstrated that the -838A allele of the p27kip1
gene is associated with MI, we sought to determine
whether the -838C>A genetic variation has functional
consequences. Because this SNP lies within the promoter
region, we examined in transiently transfected Jurkat cells
the activity of reporter constructs driven by the human
p27kip1 gene promoter containing either nucleotide A or C
at position -838. We generated two different pGL3-p27kip1
constructs for each A and C alleles (pGL3-p27kip1
A and
pGL3-p27kip1
C, respectively), and performed three
Single-strand conformation analysis of the -838C>A poly- morphism within the human p27kip1 gene Figure 1
Single-strand conformation analysis of the -838C>A 
polymorphism within the human p27kip1 gene. Note 
the distinct electrophoretic patterns for AA homozygotes, 
CC homozygotes, and CA heterozygotes.
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independent transfections with each construct. To correct
for differences in transfection efficiency, cells were
cotransfected with a plasmid encoding for the green fluo-
rescent protein (GFP) (see Methods). After normalizing
luciferase activity by the internal GFP control, the average
transcriptional activity of pGL3-p27kip1
A was 34% less
than that of pGL3-p27kip1
C (P = 0.04) (Fig. 2).
Discussion
VSMC and macrophage proliferation within the artery
wall is a major event in the development of the atheroscle-
rotic lesion, a pathological hallmark of coronary artery
disease. The CKI p27kip1 is a tumour suppressor that func-
tions as a brake against excessive cell proliferation [2].
Several recent studies have suggested an important role for
p27kip1 as a negative regulator of arterial cell proliferation
and atheroma development. First, both whole body
genetic ablation of p27kip1 and selective p27kip1 inactiva-
tion in haematopoietic precursors increase neointimal
cell proliferation and accelerates atherosclerosis in fat-fed
apoE-null mice [11,12]. Second, evidence has been
presented suggesting that p27kip1 expression and arterial
cell proliferation are inversely correlated within human
neointimal lesions [8-10].
In addition to environmental risk factors, such as smok-
ing, hypertension, and hypercholesterolaemia, genetic
factors may also increase the risk of atherosclerosis and
associated ischaemic events. For example, evidence exists
indicating that polymorphisms in the components of the
renin–angiotensin system, nitric oxide synthases, apoli-
poproteins, and several cytokines/chemokines and
growth factors could modulate the risk of suffering an epi-
sode of MI. Genetic variations must fulfil two criteria to be
considered candidate modifiers of cardiovascular risk: the
corresponding gene encodes a protein involved in vascu-
lar physiology or in atheroma development, and the
nucleotide change affects gene expression and/or func-
tion. In the present study, we have investigated whether
genetic variations within the p27kip1 are associated with
increased risk of MI. Among the three SNPs described
here, only -838C>A showed differences in allele frequency
Table 1: Primers used to amplify the p27kip1 gene for single-strand conformation analysis (SSCA).
Amplified sequence Primer sequence* Annealing temperature PCR product length (bp)
promoter P5-F: GGAGGAAGGAAGGAGCTGTTGTA
P5-R: AAGCCAAAGCGAACGTCTTTC
62°C 360
promoter P4-F: ATGATAAGTGCCGCGTCTACTCCT 
P4-F: ACCAGAGGACCGCGAAGGT
62°C 310
promoter P3-F: GGCCGAGCTGGGGGCAGCT 
P3-R: TTAACCTGGCCCCGGCGC
66°C 362
promoter P2-F: TCGGGGAGGCGGCGCGCTCG 
P2-R: AGAGGGTGGCAAAGCCCGTC
62°C 360
promoter P1-F: TGGGTTCGCGGGACCGCG 
P1-R: CTGCCTGGCGTCCATCCG
62°C 385
Exon 1 E1-F: TGCGAGTGTCTAACGGGAGC 
E1-R: TTACCGTCGGTTGCAGGTC
58°C 472
Exon 2 E2-F: TAAAGATTGTGTGTTCTTTTTAA 
E2-R: TATCGTGAGGTCTGAAGGCC
55°C 230
* F: forward; R, reverse.
Table 2: Primers used to genotype the single-nucleotide polymorphisms (SNPs).
SNP Primer sequence* Annealing temperature 
(Enzyme)
PCR product length after digestion (bp)
-838C>A F: TCCAGGTCCCGGCTTCCCGGt** 
R: CCTGCTCTGGCTGGCCTCGGAG
65°C (TaqI) 177 (A allele) 153+24 (C allele)
-79C>T F: TGATCAGCGGAGACTCGGCG 
R:CTGCCTGGCGTCCATCCG
58°C (HaeIII) 275 (T allele) 140+135 (C allele)
+326T>G (V109G) F: TGCGAGTGTCTAACGGGAGC 
R: TTACCGTCGGTTGCAGGTC
58°C (BglI) 472 (T allele) 316+156 (G allele)
* F: forward; R, reverse. ** A mismatch to create a TaqI site when -838C is present is shown in lower case.BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/5
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between cases and controls. Carriers of the -838A allele
(AA+AC genotypes) would have an almost twofold risk of
suffering an episode of MI compared to controls (OR =
1.73; 95%CI = 1.12–2.70), and the risk increased to two-
fold for AA homozygous (OR = 2.27; 95%CI = 1.26–4.10;
AA versus CC).
Because -838C>A lies within the promoter region of
p27kip1, we examined whether this SNP affects p27kip1
gene expression. Transient transfection experiments
revealed a 34% reduction in promoter activity for -838A
compared with the -838C allele. Thus, reduced p27kip1
expression in -838A carriers might facilitate neointimal
hyperplasia and therefore accelerate atheroma progres-
sion and increase the risk of MI. Distinct transcription
factor binding and/or activity may contribute to the differ-
ence in -838A and -838C p27kip1  promoter activity.
Indeed, analysis of the promoter sequence containing the
-838C>A SNP using the MatInspector v2.2 and TRANS-
FAC v7.3 software revealed potential binding sites for
several transcription factors, including STAT and IK-2.
However, additional studies are required to conclusively
address whether specific transcription factors are involved
in different transcriptional activation of -838A versus -
838C. These studies should provide valuable insight not
only for atherosclerosis but also for cancer, as p27kip1
expression appears to be altered in some human tumors
[18,19].
The use of SSCA to identify p27kip1 SNPs may be a limita-
tion of our study, because this technique apparently fails
to identify approximately 20% of SNPs. Therefore, addi-
tional functionally relevant p27kip1 SNPs may exist. We
also recognize that the number of cases analysed in our
study is limited. This was mostly because we included
only patients with angiographically diseased vessels, a
strategy that was deemed important because p27kip1 has
been involved in the control of neointimal thickening [8-
12]. The possibility of false-positive results due to popula-
tion stratification must be considered in association stud-
ies, but this is unlikely to occur in our study because we
analysed individuals from a homogeneous white popula-
tion. In addition, genotype frequencies were in the
Hardy–Weinberg equilibrium in both groups, suggesting
that the observed frequencies are representative of cases
and controls.
Conclusions
Three polymorphisms of the human p27kip1  gene (-
838C>A, -79C>T, and V109G) were analysed as candi-
dates to modify the risk of suffering MI. We found a signif-
icantly higher frequency of the -838A carriers in MI
patients compared to controls. Importantly, this
polymorphism was associated with reduced basal
p27kip1gene promoter activity. We suggest that reduced
Transcriptional activity in Jurkat cells transfected with luci- ferase reporter gene constructs driven by the p27kip1 gene  promoter containing the -838C or A allelic variants Figure 2
Transcriptional activity in Jurkat cells transfected 
with luciferase reporter gene constructs driven by 
the p27kip1 gene promoter containing the -838C or A 
allelic variants. Luciferase activity was normalized by the 
internal control green fluorescent protein. Data represent 
the means ± SD of six independent transfections (P = 0.04 in 
t-test).
Table 3: Genotype frequencies for the -838C>A, -79C>T, and 
V109G p27kip1 single-nucleotide polymorphisms (SNPs).
-838C>A*
CC CA AA
Patients 47 (26%) 88 (49%) 45 (25%)
Controls 95 (38%) 115 (46%) 40 (16%)
-79C>T
CC CT TT
Patients 99 (55%) 70 (39%) 11 (6%)
Controls 152 (61%) 82 (32%) 16 (7%)
V109G
VV VG GG
Patients 100 (55%) 71 (40%) 9 (5%)
Controls 143 (57%) 98 (39%) 9 (4%)
*P = 0.009; OR = 1.73, 95%CI = 1.12–2.70 (AA+AC) vs CC. For each 
SNP, the table shows the total number of cases for each genotype and 
their relative frequencies among controls and patients with myocardial 
infarction.
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p27kip1 expression in -838A carriers may facilitate the pro-
liferative response associated with atherosclerosis, thus
increasing the risk of MI in these individuals.
Methods
Subjects
A total of 180 patients who had suffered an episode of MI
were included in the present study. All patients were male,
no more than 55 years of age, and had at least one angio-
graphically diseased vessel (a vessel was considered dis-
eased when the angiography showed a narrowing of at
least 70% in the lumen diameter). These patients were
recruited for a search of genetic factors involved in MI
[20].
The control group consisted of 250 healthy males younger
than 55 years (blood bank donors and Hospital Universi-
tario Central de Asturias staff). Although control subjects
did not have a history of cardiovascular disease, they were
not angiographically analysed to exclude the presence of
diseased vessels. Patients and controls were white and
were all from the same region (Asturias, northern Spain, 1
million total population) and gave their informed con-
sent to participate in the study, which was approved by
the Ethical Committee of the Hospital Universitario Cen-
tral de Asturias.
Identification and genotyping of SNPs within the human 
p27kip1 gene
Genomic DNA was obtained from each individual
included in the study. In the search for p27kip1 SNPs, we
analysed 50 patients and 50 controls using SSCA. The
entire p27kip1 coding sequence and 1500 nucleotides of
the promoter region were amplified in overlapping frag-
ments of 300–450 base pairs by PCR (Table 1 shows the
sequences of the PCR primers; the sequence of the p27kip1
gene was obtained from http://ncbi.nlm.nih.gov, acces-
sion number NT009714). SSCA analysis was performed as
previously described [21]. The DNA from samples show-
ing atypical electrophoretic patterns was amplified, puri-
fied, and sequenced using an automated ABI310 system.
For genotyping of the three SNPs in patients and controls,
genomic DNA was amplified by PCR to generate DNA
fragments containing the SNP, and these fragments were
digested with restriction enzymes that produced distinct
patterns of digestion depending on the allele present
(primers and restriction enzymes are listed in Table 2).
The digested fragments were electrophoresed on 3% agar-
ose gels, and the pattern corresponding to each individual
was visualized after ethidium bromide staining of the gel.
Construction of p27kip1 reporter vectors
DNA fragments from the 5' flanking region of the
p27kip1gene between nucleotides – 1100 to -27, contain-
ing either C or A at -838, were generated through PCR of
two CC and AA homozygous individuals with forward
(TATGATGGTACCAGACGTTCGCTTTGGCTTC) and
reverse (GCACGAAAGCTTCTCTCGCACTCTCAAAAA)
primers containing KpnI and HindIII sites, respectively.
The PCR products were cloned into the pGL3-Basic plas-
mid (Promega, Madison, WI, USA) to generate pGL3-
p27kip1
C (-838C) and pGL3-p27kip1
A (-838A). For each
genotype, two plasmids were generated and confirmed by
direct sequencing.
Cell culture and luciferase reporter gene assays
Jurkat cells (American Type Culture Collection) were
incubated at 37°C in a humidified 5% CO2–95% O2
atmosphere in RPMI medium supplemented with 100U/
ml penicillin, 0.1 mg/ml streptomycin, 2 mmol/l L-
glutamine, and 10% fetal calf serum. Transfections were
performed with SuperFect Transfection Reagent following
the manufacturer's protocol (Quiagen, Valencia, CA,
USA). In a blinded manner, the promoter/luciferase
reporter gene (2  µg) was cotransfected with 1 µg of
pEGFP-N1 control vector. Three independent transfec-
tions were done for each of the four reporter genes (2
pGL3-p27kip1
C and 2 pGL3-p27kip1
A, a total of six transfec-
tions for each SNP). For luciferase activity assay, cells were
collected by centrifugation, washed twice with PBS, and
lysed with 100 µl of cell lysis reagent (Promega). Insolu-
ble protein was removed by a 10-minute centrifugation at
15,000 g, and the supernatants were immediately assayed
for luciferase activity and green fluorescence. Luciferase
assays were performed using a Victor 4120 multilabel
counter (Perkin Elmer, Boston, MA, USA) and the
Promega luciferase assay kit. Cell extract (50 µl) and 100
µl of luciferin mixture were incubated for 5 s and light
output was monitored for 5 s. For each sample, arbitrary
light units from luciferase were normalized versus the
measure of green fluorescence.
Statistical analysis
Allele and genotype frequencies in patients and controls
were compared using a chi-square test. This test was also
used to determine if the observed genotype frequencies in
cases and controls differed from those expected under the
Hardy–Weinberg equilibrium. Multivariate analysis was
used to compare the genotype and allele frequencies
between the groups according to the presence/absence of
classical risk factors. Odds ratios (OR) with 95% confi-
dence intervals (CI) were obtained to calculate the relative
risk of MI associated with the genotypes. The results of
transfections were analysed by two-tailed unpaired t-test.
All statistical analyses were performed with the SPSS sta-
tistical package (v.11.0).Publish with BioMed Central    and   every 
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